Research Institute of Molecular Pathology, Vienna Biocenter, 1030 Vienna, Austria.
University of Duisburg-Essen, Center of Medical Biotechnology, Faculty of Biology, 45141 Essen, Germany.
Cell. 2022 Jun 23;185(13):2338-2353.e18. doi: 10.1016/j.cell.2022.05.009. Epub 2022 Jun 3.
Hijacking the cellular protein degradation system offers unique opportunities for drug discovery, as exemplified by proteolysis-targeting chimeras. Despite their great promise for medical chemistry, so far, it has not been possible to reprogram the bacterial degradation machinery to interfere with microbial infections. Here, we develop small-molecule degraders, so-called BacPROTACs, that bind to the substrate receptor of the ClpC:ClpP protease, priming neo-substrates for degradation. In addition to their targeting function, BacPROTACs activate ClpC, transforming the resting unfoldase into its functional state. The induced higher-order oligomer was visualized by cryo-EM analysis, providing a structural snapshot of activated ClpC unfolding a protein substrate. Finally, drug susceptibility and degradation assays performed in mycobacteria demonstrate in vivo activity of BacPROTACs, allowing selective targeting of endogenous proteins via fusion to an established degron. In addition to guiding antibiotic discovery, the BacPROTAC technology presents a versatile research tool enabling the inducible degradation of bacterial proteins.
劫持细胞蛋白降解系统为药物发现提供了独特的机会,其中以蛋白水解靶向嵌合体为例。尽管它们在医学化学方面有很大的前景,但到目前为止,还不可能对细菌降解机制进行重新编程以干扰微生物感染。在这里,我们开发了小分子降解剂,即所谓的 BacPROTACs,它们与 ClpC:ClpP 蛋白酶的底物受体结合,为降解作用准备新的底物。除了靶向功能外,BacPROTACs 还能激活 ClpC,将休眠的解旋酶转化为其功能状态。通过冷冻电镜分析观察到诱导的高阶寡聚体,提供了激活的 ClpC 展开蛋白质底物的结构快照。最后,在分枝杆菌中进行的药物敏感性和降解测定证明了 BacPROTACs 的体内活性,允许通过融合到已建立的降解结构域来选择性靶向内源性蛋白质。除了指导抗生素的发现外,BacPROTAC 技术还提供了一种通用的研究工具,可实现细菌蛋白的诱导降解。